Anavex Life Sciences Corp. Announces its Preclinical Pipeline of Novel Oncology Therapies

Geneva, Switzerland — February 12, 2007 — Anavex Life Sciences Corp. (the “Company”) (OTCBB: AVXL) announces its strategic vision for growth by discovering and developing cutting-edge drugs against solid tumors. The Company’s innovative drug discovery and development programs have helped build a strong pipeline that targets a wide range of solid tumors, including colorectal, prostate,…

Anavex Life Sciences Corp. Appoints VP Business Development and VP Strategic Planning

Geneva, Switzerland — February 07, 2007 — Anavex Life Sciences Corp. (OTCBB: AVXL) (the “Company”) announces that Ms. Angela Vernadaki and Dr. George Kalkanis have been appointed as Officers of the Company. Ms. Vernadaki, appointed as VP Business Development, brings more than ten years of experience in marketing, sales, business development and entrepreneurship in the…

Anavex Life Sciences Corp. Outlines its Central Nervous System (CNS) Portfolio of Novel Therapeutics

Geneva, Switzerland — February 01, 2007 — Anavex Life Sciences Corp. (OTCBB: AVXL) (the “Company”) announces its strategic vision for growth by discovering and developing cutting-edge drugs against neurological diseases. The Company’s innovative drug discovery and development programs have helped build a strong pipeline that targets a range of serious neurological diseases, including Alzheimer’s Disease…